Latest Health News

Page 7 of 271
Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.
Ada Torres
Ada Torres
29 Oct 2026
Atomo Diagnostics has signed an MOU with Innovation Scientific to develop a fourth-generation HIV rapid test using its Galileo cassette. The project could add a new product to Atomo’s pipeline, but regulatory approval, clinical work and definitive commercial agreements remain outstanding.
Ada Torres
Ada Torres
29 Oct 2026
Integral Diagnostics has opened FY27 below expectations, with radiologist and sonographer shortages limiting revenue growth and pushing labour costs ahead of sales. The company expects FY27 revenue growth of 4% to 6% and a full-year operating EBITDA margin of 19.5% to 20.5%, with improvement weighted to the second half.
Ada Torres
Ada Torres
29 Oct 2026
Enlitic’s Ensight platform reached approximately US$760,000 in annualised recurring revenue as two more US deployments went live and a US$806,000 University of Michigan migration project progressed. The company also ended the quarter with US$9.453 million in cash after completing its capital raise and converting its notes into equity.
Victor Sage
Victor Sage
29 Oct 2026
BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.
Victor Sage
Victor Sage
29 Oct 2026
Me Today says more than 80% of its Series 1 warrants have been exercised, delivering $2.31 million of new capital as the nutraceuticals company forecasts stronger first-half FY27 revenue. FY26 gross revenue rose 36% to $7.96 million while the EBITDA loss narrowed substantially.
Victor Sage
Victor Sage
29 Oct 2026
Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.
Ada Torres
Ada Torres
29 Oct 2026
Freightways delivered double-digit growth across revenue and profit in FY26, but elevated fuel prices and weaker premium-service demand are now squeezing margins. The NZX and ASX-listed courier group expects volumes to remain subdued until fuel costs ease sustainably.
Victor Sage
Victor Sage
29 Oct 2026
Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.
Ada Torres
Ada Torres
28 Oct 2026
Comvita has moved from NZ$62.4 million of net debt to NZ$0.5 million of net cash in a year, while FY27 first-quarter sales rose 4.6%. The sharper test now is whether its operating reset can convert a stronger balance sheet into durable shareholder returns, with no FY27 dividend expected and board control still contested.
Victor Sage
Victor Sage
28 Oct 2026
Thrive Tribe Technologies has made progress on its defence and veteran software ambitions, but ended September with just A$20,000 in cash after a A$573,000 operating outflow. Its proposed A$2 million placement remains uncommitted and requires shareholder approval in November.
Sophie Babbage
Sophie Babbage
28 Oct 2026
IMEXHS has moved several proprietary AI agents into live customer use while delivering stronger revenue, earnings and operating cash flow in the third quarter. But software bookings fell sharply, ARR was flat after churn, and Colombian receivables remain a material cash risk.
Victor Sage
Victor Sage
28 Oct 2026

Browse the archive

Full archive